Home Artificial Intelligence Recursion Pharmaceuticals CEO cites how AI could lift drug business

Recursion Pharmaceuticals CEO cites how AI could lift drug business

“I think with clinical trials, there’s still going to be a few years to get through the clinical trial space,” Gibson said. “But, to find the drug and get it into the clinic, I think we can shorten that from five or six years and hundreds of millions of dollars into, perhaps, one or two years and just $10 million or $20 million.”

Recursion is currently developing a new drug to treat cerebral cavernous malformation, a neurovascular disease that Gibson said is not widely known but affects six times as many people in the U.S. than cystic fibrosis. Before Recursion’s AI-focused approach, there wasn’t a clear path toward making a drug to successfully tackle this disease, he said. The new treatment is almost done with its phase two trials.

Gibson said he thinks the use of this new technology to map biology will be common in the biopharma industry in five or 10 years.

“Think of it as, like, Google Street View driving around taking pictures of everything,” he said. “We have microscopes taking tens of millions of pictures of cells every week, and we’re using a lot of the same AI algorithms to turn those images into mathematical representations of biology that we think could unlock some really exciting secrets.”

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer The CNBC Investing Club Charitable Trust holds shares of Nvidia.



Denial of responsibility! TechCodex is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
DMCA compliant image

Leave a Comment